Jazz Pharmaceuticals PLC Cash Flow Conversion Efficiency
Jazz Pharmaceuticals PLC cash flow conversion efficiency. Based on the latest financial reports, Jazz Pharmaceuticals PLC (JAZZ) has a cash flow conversion efficiency ratio of 0.090x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($408.20 Million) by net assets ($4.53 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Jazz Pharmaceuticals PLC (2005–2025)
Cash flow conversion efficiency of Jazz Pharmaceuticals PLC from 2005 to 2025. This chart illustrates how Jazz Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Jazz Pharmaceuticals PLC for real-time trading data and today's change.
Jazz Pharmaceuticals PLC Cash Flow Conversion Ratio Explained
Jazz Pharmaceuticals PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jazz Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jazz Pharmaceuticals PLC ranked by their cash flow conversion efficiency. Also see JAZZ market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zydus Lifesciences Limited
NSE:ZYDUSLIFE
|
0.014x |
|
LTIMindtree Limited
NSE:LTM
|
0.150x |
|
China Satellite Communications Co Ltd
SHG:601698
|
0.017x |
|
Huazhu Group Ltd
NASDAQ:HTHT
|
0.237x |
|
TKO Group Holdings, Inc.
NYSE:TKO
|
0.081x |
|
Mr. Cooper Group Inc
NASDAQ:COOP
|
0.058x |
|
Hasbro Inc
NASDAQ:HAS
|
0.501x |
|
Coeur Mining Inc
NYSE:CDE
|
0.049x |
Annual Cash Flow Conversion Efficiency for Jazz Pharmaceuticals PLC (2005–2025)
The table below shows the annual cash flow conversion efficiency of Jazz Pharmaceuticals PLC from 2005 to 2025. Review JAZZ free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.32 Billion | $1.36 Billion | 0.314x | -7.93% |
| 2024-12-31 | $4.09 Billion | $1.40 Billion | 0.341x | +16.69% |
| 2023-12-31 | $3.74 Billion | $1.09 Billion | 0.292x | -29.11% |
| 2022-12-31 | $3.09 Billion | $1.27 Billion | 0.412x | +109.95% |
| 2021-12-31 | $3.97 Billion | $778.51 Million | 0.196x | -20.13% |
| 2020-12-31 | $3.66 Billion | $899.65 Million | 0.246x | -1.50% |
| 2019-12-31 | $3.11 Billion | $776.40 Million | 0.250x | -13.86% |
| 2018-12-31 | $2.76 Billion | $798.90 Million | 0.290x | +13.41% |
| 2017-12-31 | $2.71 Billion | $693.09 Million | 0.255x | -18.79% |
| 2016-12-31 | $1.88 Billion | $590.54 Million | 0.315x | -5.47% |
| 2015-12-31 | $1.60 Billion | $531.94 Million | 0.333x | +12.45% |
| 2014-12-31 | $1.37 Billion | $405.76 Million | 0.296x | +35.17% |
| 2013-12-31 | $1.30 Billion | $283.62 Million | 0.219x | -1.71% |
| 2012-12-31 | $1.12 Billion | $249.75 Million | 0.223x | -71.67% |
| 2011-12-31 | $192.79 Million | $151.60 Million | 0.786x | -59.19% |
| 2010-12-31 | $30.55 Million | $58.87 Million | 1.927x | +783.83% |
| 2009-12-31 | $-72.83 Million | $-15.88 Million | 0.218x | -84.45% |
| 2008-12-31 | $-92.88 Million | $-130.23 Million | 1.402x | +195.09% |
| 2007-12-31 | $54.99 Million | $-81.09 Million | -1.475x | -553.30% |
| 2006-12-31 | $-176.30 Million | $-57.35 Million | 0.325x | -26.26% |
| 2005-12-31 | $-118.25 Million | $-52.16 Million | 0.441x | -- |
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC)… Read more